LPCAT1 and MRPL9 Promote Hepatocellular Carcinoma Progression via AKT Phosphorylation and Define a Mitochondrial Prognostic Model
Open Access
Abstract
Background/Objectives: Mitochondrial dysfunction plays a critical role in hepatocellular carcinoma (HCC) progression. This study aimed to identify mitochondrial-related prognostic genes and elucidate their functional mechanisms in HCC. Methods: Mitochondrial-related prognostic genes were screened from the TCGA and ICGC-LIHC cohorts. A prognostic risk model was constructed and validated in three external cohorts. Immunotherapy sensitivity between high- and low-risk groups was assessed using somatic mutation and immune infiltration analyses. Underlying molecular mechanisms were further validated through in vitro experiments in HCC cell lines. Results: Transcriptome analysis identified 15 mitochondrial-related prognostic genes, from which 10 candidates were refined using LASSO regression. Among them, LPCAT1 and MRPL9 were significantly associated with overall survival. The 2-MRG model (comprising LPCAT1 and MRPL9) demonstrated superior prognostic accuracy and better survival stratification across both internal and external cohorts. Functional enrichment analysis revealed significant metabolic dysfunction in the high-risk group. The high-risk group also exhibited a significantly higher tumor mutation burden and an enhanced predicted responsiveness to immunotherapy. In vitro, knockdown of MRPL9 or LPCAT1 inhibited the proliferation and migration of HCC cells by inducing G1/S arrest and G2/M arrest, respectively. Moreover, they also suppressed the AKT phosphorylation. Conclusions: We developed a robust 2-MRG prognostic model based on LPCAT1 and MRPL9 that effectively predicts HCC outcomes and supports individualized therapeutic decision-making. Both genes promote HCC progression by modulating the AKT phosphorylation and cell-cycle checkpoints, highlighting their potential as therapeutic targets.Keywords
Funding Information
- National Natural Science Foundation of China (82072689)
- National Natural Science Foundation of China (82300710)
- Science Foundation of Sichuan (2026NSFSC0664)
- Science Foundation of Sichuan (2024NSFSC1692)
- Sichuan Province Science and Technology Department Project (2025ZNSFSC1884)
- China Postdoctoral Science Foundation (2023M742465)
This publication has 39 references indexed in Scilit:
- Amplifying Anti‐Tumor Immune Responses via Mitochondria‐Targeting Near‐Infrared Photodynamic TherapyAdvanced Science, 2025
- Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept studyJournal of Gastroenterology, 2025
- APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024Hepatology International, 2024
- Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?Drug Resistance Updates, 2021
- The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerCancer Cell, 2020
- LPCAT1 functions as a novel prognostic molecular marker in hepatocellular carcinomaGenes & Diseases, 2020
- Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid RemodelingCell Metabolism, 2019
- The process of mammalian mitochondrial protein synthesisCell and tissue research, 2016
- Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progressionHepatology, 2016
- Lysophospholipid Acyltransferases Mediate Phosphatidylcholine Diversification to Achieve the Physical Properties Required In VivoCell Metabolism, 2014